Year |
Citation |
Score |
2023 |
Clark AG, Bertrand FE, Sigounas G. A potential requirement for Smad3 phosphorylation in Notch-mediated EMT in colon cancer. Advances in Biological Regulation. 88: 100957. PMID 36739740 DOI: 10.1016/j.jbior.2023.100957 |
0.312 |
|
2020 |
Bertrand FE. The cross-talk of NOTCH and GSK-3 signaling in colon and other cancers. Biochimica Et Biophysica Acta. Molecular Cell Research. 118738. PMID 32389646 DOI: 10.1016/J.Bbamcr.2020.118738 |
0.373 |
|
2017 |
Sigounas G, Bertrand FE, Weidner DA, Vinson KE, Clark AG, Khan A. Abstract 856: Notch-1 promotes a mesenchymal phenotype in colon cancer cells via Notch-3 and Smad-3 activation Cancer Research. 77: 856-856. DOI: 10.1158/1538-7445.Am2017-856 |
0.386 |
|
2015 |
Vinson KE, George DC, Fender AW, Bertrand FE, Sigounas G. The Notch pathway in colorectal cancer. International Journal of Cancer. Journal International Du Cancer. PMID 26264352 DOI: 10.1002/Ijc.29800 |
0.335 |
|
2015 |
Fender AW, Nutter JM, Fitzgerald TL, Bertrand FE, Sigounas G. Notch-1 promotes stemness and epithelial to mesenchymal transition in colorectal cancer. Journal of Cellular Biochemistry. 116: 2517-27. PMID 25914224 DOI: 10.1002/Jcb.25196 |
0.446 |
|
2014 |
Bertrand FE, McCubrey JA, Angus CW, Nutter JM, Sigounas G. NOTCH and PTEN in prostate cancer. Advances in Biological Regulation. 56: 51-65. PMID 24933481 DOI: 10.1016/J.Jbior.2014.05.002 |
0.416 |
|
2014 |
McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Rakus D, Gizak A, Demidenko ZN, et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget. 5: 2881-911. PMID 24931005 DOI: 10.18632/Oncotarget.2037 |
0.37 |
|
2014 |
McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Cocco L, Cervello M, Martelli AM. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia. 28: 15-33. PMID 23778311 DOI: 10.1038/Leu.2013.184 |
0.408 |
|
2014 |
Fender A, Nutter M, Fitzgerald T, Bertrand F, Sigounas G. Abstract 1952: Notch-1 regulated stemness and EMT in colorectal cancer Cancer Research. 74: 1952-1952. DOI: 10.1158/1538-7445.Am2014-1952 |
0.446 |
|
2014 |
Nutter JM, Angus CW, Bertrand FE. Abstract 1566: Notch-1 regulation of the PTEN - mTOR axis in prostate Cancer Research. 74: 1566-1566. DOI: 10.1158/1538-7445.Am2014-1566 |
0.495 |
|
2012 |
Bertrand FE, Angus CW, Partis WJ, Sigounas G. Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle (Georgetown, Tex.). 11: 4344-51. PMID 23032367 DOI: 10.4161/Cc.22134 |
0.382 |
|
2011 |
Angus CW, Willis DF, Salvador WD, Bertrand FE. Abstract 497: Loss of Notch-1 expression in human prostate epithelial cells results in reduced PTEN expression and altered differentiative capacity Cancer Research. 71: 497-497. DOI: 10.1158/1538-7445.Am2011-497 |
0.538 |
|
2009 |
Whelan JT, Kellogg A, Shewchuk BM, Hewan-Lowe K, Bertrand FE. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. Journal of Cellular Biochemistry. 107: 992-1001. PMID 19479935 DOI: 10.1002/Jcb.22199 |
0.732 |
|
2009 |
Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, Nicoletti F, Stivala F, Milella M, Tafuri A, Cervello M, Martelli AM, McCubrey JA. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia. 23: 25-42. PMID 18800146 DOI: 10.1038/Leu.2008.246 |
0.382 |
|
2008 |
Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, McCubrey JA. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia. 22: 686-707. PMID 18337767 DOI: 10.1038/Leu.2008.26 |
0.735 |
|
2008 |
McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia. 22: 708-22. PMID 18337766 DOI: 10.1038/Leu.2008.27 |
0.424 |
|
2008 |
Whelan JT, Ludwig DL, Bertrand FE. HoxA9 induces insulin-like growth factor-1 receptor expression in B-lineage acute lymphoblastic leukemia. Leukemia. 22: 1161-9. PMID 18337761 DOI: 10.1038/Leu.2008.57 |
0.753 |
|
2007 |
Whelan JT, Forbes SL, Bertrand FE. CBF-1 (RBP-J kappa) binds to the PTEN promoter and regulates PTEN gene expression. Cell Cycle (Georgetown, Tex.). 6: 80-4. PMID 17245125 DOI: 10.4161/Cc.6.1.3648 |
0.754 |
|
2007 |
Whelan JT, Ludwig DL, Bertrand FE. HoxA9 Induces Insulin-Like Growth Factor-1 Receptor (IGF-1R) Expression in Acute Leukemia. Blood. 110: 3343-3343. DOI: 10.1182/Blood.V110.11.3343.3343 |
0.753 |
|
2007 |
McCubrey JA, Bertrand FE, Steelman LS, Chang F, Terrian DM, Franklin RA. Critical roles of the Raf/MEK/ERK pathway in apoptosis and drug resistance Apoptosis, Cell Signaling, and Human Diseases. 2: 101-134. DOI: 10.1007/978-1-59745-199-4_5 |
0.342 |
|
2006 |
Basecke J, Whelan JT, Griesinger F, Bertrand FE. The MLL partial tandem duplication in acute myeloid leukaemia. British Journal of Haematology. 135: 438-49. PMID 16965385 DOI: 10.1111/J.1365-2141.2006.06301.X |
0.701 |
|
2006 |
McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Advances in Enzyme Regulation. 46: 249-279. PMID 16854453 DOI: 10.1016/J.Advenzreg.2006.01.004 |
0.488 |
|
2006 |
Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, Ludwig DL, McCubrey JA. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia. 20: 1254-60. PMID 16642049 DOI: 10.1038/Sj.Leu.2404217 |
0.402 |
|
2005 |
Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M, McCubrey JA. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? Expert Opinion On Therapeutic Targets. 9: 1009-30. PMID 16185155 DOI: 10.1517/14728222.9.5.1009 |
0.357 |
|
2005 |
Chappell WH, Green TD, Spengeman JD, McCubrey JA, Akula SM, Bertrand FE. Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1. Cell Cycle (Georgetown, Tex.). 4: 1389-95. PMID 16096376 DOI: 10.4161/Cc.4.10.2028 |
0.5 |
|
2005 |
McCubrey JA, Bertrand FE. Upping the bid on engineered inducible cell death. Cancer Biology & Therapy. 4: 537. PMID 15970693 DOI: 10.4161/Cbt.4.5.1863 |
0.316 |
|
2005 |
Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Franklin RA, Bertrand FE, McMahon M, McCubrey JA. Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle (Georgetown, Tex.). 4: 822-30. PMID 15917660 DOI: 10.4161/Cc.4.6.1724 |
0.404 |
|
2005 |
Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Bertrand FE, Franklin RA, McCubrey JA. Effects of endogenous epidermal growth factor receptor signaling on DNA synthesis and ERK activation in a cytokine-dependent hematopoietic cell line. Cell Cycle (Georgetown, Tex.). 4: 818-21. PMID 15908804 DOI: 10.4161/Cc.4.6.1723 |
0.441 |
|
2005 |
Spengeman JD, Green TD, McCubrey JA, Bertrand FE. Activated EGFR promotes the survival of B-lineage acute leukemia in the absence of stromal cells. Cell Cycle (Georgetown, Tex.). 4: 483-7. PMID 15701973 DOI: 10.4161/Cc.4.3.1533 |
0.479 |
|
2005 |
Bertrand FE, Spengemen JD, Shelton JG, McCubrey JA. Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support. Leukemia. 19: 98-102. PMID 15496972 DOI: 10.1038/Sj.Leu.2403560 |
0.468 |
|
2005 |
Libra M, Mazzarino MC, De Re V, Steelman LS, Abrams SL, Bertrand FE, Shelton JG, Molton S, McMahon M, McCubrey JA. Role of BRAF Mutations in Hematopoietic Malignancies and the Induction of Cytokine-Independence-Synergy with PI3K/Akt Pathway. Blood. 106: 4291-4291. DOI: 10.1182/Blood.V106.11.4291.4291 |
0.433 |
|
2005 |
Abrams SL, Steelman LS, Shelton JG, Chappell WH, Wong EW, Bertrand FE, McCubrey JA. Key Roles of the Raf-1 and Akt in Drug Resistance, Cell Cycle Progression and the Prevention of Apoptosis in Hematopoietic Cells. Blood. 106: 1356-1356. DOI: 10.1182/Blood.V106.11.1356.1356 |
0.404 |
|
2004 |
Steelman LS, Bertrand FE, McCubrey JA. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opinion On Therapeutic Targets. 8: 537-50. PMID 15584861 DOI: 10.1517/14728222.8.6.537 |
0.391 |
|
2004 |
Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 18: 189-218. PMID 14737178 DOI: 10.1038/Sj.Leu.2403241 |
0.445 |
|
2003 |
Bertrand FE, Spengeman JD, Shah N, LeBien TW. B-cell development in the presence of the MLL/AF4 oncoprotein proceeds in the absence of HOX A7 and HOX A9 expression Leukemia. 17: 2454-2459. PMID 14562113 DOI: 10.1038/Sj.Leu.2403178 |
0.436 |
|
2001 |
Bertrand FE, Vogtenhuber C, Shah N, LeBien TW. Pro-B-cell to pre-B-cell development in B-lineage acute lymphoblastic leukemia expressing the MLL/AF4 fusion protein. Blood. 98: 3398-405. PMID 11719380 DOI: 10.1182/Blood.V98.12.3398 |
0.45 |
|
2001 |
Golub R, Martin D, Bertrand FE, Cascalho M, Wabl M, Wu GE. VH gene replacement in thymocytes. Journal of Immunology (Baltimore, Md. : 1950). 166: 855-60. PMID 11145660 DOI: 10.4049/Jimmunol.166.2.855 |
0.313 |
|
2000 |
Bertrand FE, Eckfeldt CE, Lysholm AS, LeBien TW. Notch-1 and Notch-2 exhibit unique patterns of expression in human B-lineage cells. Leukemia. 14: 2095-102. PMID 11187898 DOI: 10.1038/Sj.Leu.2401942 |
0.456 |
|
2000 |
Bertrand FE, Eckfeldt CE, Fink JR, Lysholm AS, Pribyl JA, Shah N, LeBien TW. Microenvironmental influences on human B-cell development. Immunological Reviews. 175: 175-86. PMID 10933602 DOI: 10.1111/J.1600-065X.2000.Imr017513.X |
0.426 |
|
1997 |
Bertrand FE, Billips LG, Burrows PD, Gartland GL, Kubagawa H, Schroeder HW. Ig DH Gene Segment Transcription and Rearrangement Before Surface Expression of the Pan-B–Cell Marker CD19 in Normal Human Bone Marrow Blood. 90: 736-744. DOI: 10.1182/Blood.V90.2.736.736_736_744 |
0.346 |
|
1995 |
Billips LG, Nuñez CA, Bertrand FE, Stankovic AK, Gartland GL, Burrows PD, Cooper MD. Immunoglobulin recombinase gene activity is modulated reciprocally by interleukin 7 and CD19 in B cell progenitors. The Journal of Experimental Medicine. 182: 973-82. PMID 7561700 DOI: 10.1084/Jem.182.4.973 |
0.382 |
|
1995 |
Bertrand FE, Billips LG, Schroeder HW. Analysis of DHQ52 gene segment transcription and rearrangement during B-cell development in human fetal bone marrow. Annals of the New York Academy of Sciences. 764: 228-30. PMID 7486529 DOI: 10.1111/J.1749-6632.1995.Tb55832.X |
0.345 |
|
Show low-probability matches. |